MedTrace Logo

Intraumbilical Misoprostol in Retained Placenta

NCT01840813 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2013-11-05

No results posted yet for this study

Summary

Administration of intraumbilical misoprostol to women with retained placenta despite active management of third stage of labour reduces the need for manual removal of placenta and the amount of blood loss vaginally.

Conditions

  • Retained Placenta

Interventions

DRUG

Misoprostol

It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.

DRUG

Normal saline

It is a placebo group

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Shahla K. Alalaf, Clinical M.D · Hawler Medical University

  • Sheelan S Rajab, High Diploma · , Shaheed Dr.Khalid General Hospital, Directorate of Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01840813 on ClinicalTrials.gov